![]() |
市场调查报告书
商品编码
1949528
微孔盘系统市场 - 全球产业规模、份额、趋势、机会及预测(按产品、应用、最终用户、地区和竞争格局划分),2021-2031年Microplate Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By End User, By Region & Competition, 2021-2031F |
||||||
全球微孔盘系统市场预计将从 2025 年的 26.7 亿美元成长到 2031 年的 37.4 亿美元,复合年增长率为 5.76%。
这些系统由洗板机、读数仪和自动化处理设备等实验室设备组成,对于分析高密度多孔板样品至关重要。推动其发展的主要因素是药物研发中对高通量筛检日益增长的需求以及基因组研究的不断扩展,而生物製药行业的巨额投资也为此提供了支持。例如,欧洲製药工业协会联合会 (EFPIA) 估计,到 2024 年,欧洲以研发为基础的製药业将在研发方面投入 550 亿欧元,这凸显了该产业对高效分析技术在优化工作流程方面的高度依赖。
| 市场概览 | |
|---|---|
| 预测期 | 2027-2031 |
| 市场规模:2025年 | 26.7亿美元 |
| 市场规模:2031年 | 37.4亿美元 |
| 复合年增长率:2026-2031年 | 5.76% |
| 成长最快的细分市场 | 微孔盘读数仪 |
| 最大的市场 | 北美洲 |
然而,由于部署自动化设备需要大量资金投入,市场面临许多障碍。购买和维护整合机器人系统和多模式读取器的高昂成本,对于预算有限的学术机构和小规模实验室而言,无疑是一大难题。这一经济障碍限制了全自动解决方案的广泛应用,迫使许多机构依赖吞吐量较低的半自动或手动替代方案。因此,成本敏感性仍然是一个重要的阻碍因素,阻碍了这些先进系统进一步渗透到资源有限的研究环境中。
製药和生物技术领域研发投入的不断成长是全球微孔盘系统市场的主要驱动力。由于实验室需要筛检庞大的化合物库,因此越来越依赖基于微孔盘的检测方法来识别候选治疗药物,这需要对先进的分析工具和技术进行大量投资。根据赛默飞世尔科技公司于2025年4月发布的2024年度报告,该公司将投入14亿美元用于研发,以促进生命科学领域的创新,凸显了高效检测平台的紧迫性。此外,丹纳赫公司在2025年公布的2024年全年销售额为239亿美元,反映了利用这些高密度微孔板技术的生命科学和诊断解决方案的巨大规模。
此外,对工作流程效率和实验室自动化日益增长的需求正在加速整合式微孔盘系统的应用。实验室越来越多地采用全自动解决方案来减少人为错误并最大限度地提高通量,这一转变也体现在专注于自动化工作流程和实验室服务的行业收入的增长上。例如,安捷伦科技公司在其2024年11月发布的「2024财年第四季」财务报告中指出,其安捷伦CrossLab集团全年营收达到16.4亿美元(年增5%)。这一成长显示了业界对效率的追求,也证实了微孔盘技术在竞争激烈的环境中继续发挥至关重要的作用,能够帮助企业实现所需的精确度和速度。
全球微孔盘系统市场成长的主要障碍之一是自动化设备所需的大量资本投入。机器人液体处理设备和高效能多功能读板机价格昂贵,往往超出学术机构和中小型生物技术公司的预算。这种资金限制迫使注重成本的企业依赖半自动化或手动工作流程,而这些流程本身就限制了营运效率和吞吐量。因此,采用完全整合解决方案主要局限于资金雄厚的製药公司,这使得很大一部分潜在用户无法升级到先进的自动化平台。
公共研究领域资金停滞不前,进一步加剧了新技术推广应用的障碍。美国科学促进会宣布,美国国立卫生研究院2024年的常规预算为471亿美元,这一数字反映了通货膨胀导致的实际购买力停滞不前。预算限制迫使研究机构延迟资本密集型设备的采购。这种财政保守主义减缓了旧有系统的更新换代速度,并抑制了资源受限研究领域的整体市场成长。
将人工智慧 (AI) 整合到微孔盘分析软体中,透过自动化量化复杂的表型结果,正在革新数据解读方式。为了管理高内涵筛检资料集,实验室正在利用机器学习演算法,从而消除人工检验的瓶颈,并提高检测结果的可重复性。这项技术变革得益于旨在管理资料密集型工作流程的专用资讯学解决方案的快速普及。 2024 年 11 月,Revvity 在投资者日上宣布,其纯 SaaS 软体平台 Signals 的年度经常性收入复合年增长率 (CAGR) 已达到 12%,凸显了现代实验室对智慧数据工具日益增长的需求。
同时,微孔盘系统在个人化医疗工作流程中的应用日益广泛,其应用范围已从上游研究显着转向下游临床诊断。临床检查室正利用多孔板进行生物标记检验和大规模基因测序,这对于基于特定分子谱的患者分层至关重要。这种向诊断领域的拓展带来了稳定的收入来源,使其不受研发预算波动的影响,并得益于精准医疗对常规检测的需求。根据Bio-Rad Laboratories于2025年2月发布的“2024财年第四季及全年财务业绩报告”,临床诊断部门全年净销售额为15.4亿美元,年增3.7%。这一成长主要归功于临床环境中检测产品和耗材需求的增加。
The Global Microplate Systems Market is projected to expand from USD 2.67 Billion in 2025 to USD 3.74 Billion by 2031, registering a CAGR of 5.76%. Comprising laboratory tools such as washers, readers, and automated handlers, these systems are essential for analyzing high-density multi-well samples. Growth is largely fueled by the rising need for high-throughput screening in drug discovery and the expanding applications of genomic research, supported by heavy investment from the biopharmaceutical industry. For instance, the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical sector in Europe invested €55,000 million in research and development during 2024, highlighting the industry's dependence on efficient analytical technologies to optimize workflows.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.67 Billion |
| Market Size 2031 | USD 3.74 Billion |
| CAGR 2026-2031 | 5.76% |
| Fastest Growing Segment | Microplate Reader |
| Largest Market | North America |
However, the market faces a significant obstacle due to the substantial capital costs required for automated instrumentation. The high price of purchasing and maintaining integrated robotic systems and multi-mode readers can be prohibitive for academic institutions and smaller laboratories with restricted budgets. This financial hurdle limits the widespread uptake of fully automated solutions, forcing many facilities to depend on semi-automated or manual alternatives that yield lower throughput. As a result, cost sensitivity continues to be a major restraint, hindering the deeper penetration of these advanced systems into resource-limited research settings.
Market Driver
The escalating expenditure on pharmaceutical and biotechnology R&D serves as the main engine driving the Global Microplate Systems Market. As laboratories are tasked with screening immense compound libraries, there is a heightened dependence on microplate-based assays for identifying therapeutic candidates, which necessitates advanced analytical tools and substantial financial investment in technology. According to Thermo Fisher Scientific's '2024 Annual Report' released in April 2025, the company allocated $1.4 billion to research and development to foster innovation within its life sciences division, demonstrating the urgent need for efficient detection platforms. Furthermore, Danaher Corporation reported full-year 2024 revenues of $23.9 billion in 2025, reflecting the vast scale of life science and diagnostic solutions that utilize these high-density formats.
Additionally, the rising demand for improved workflow efficiency and laboratory automation is fast-tracking the uptake of integrated microplate systems. To reduce human error and maximize throughput, laboratories are increasingly adopting fully robotic solutions, a shift reflected in the growing revenues of sectors focused on automated workflows and laboratory services. For example, Agilent Technologies reported in November 2024, within its 'Fourth-Quarter Fiscal Year 2024 Financial Results', that the Agilent CrossLab Group achieved full-year revenue of $1.64 billion, a 5% increase year-over-year. This growth underscores the industry's move toward streamlined operations, ensuring microplate technologies remain fundamental to attaining the precision and speed needed in competitive research environments.
Market Challenge
A major barrier to the growth of the global microplate systems market is the significant capital expenditure necessary for automated instrumentation. Robotic liquid handlers and high-performance multi-mode readers come with premium price tags that frequently exceed the available budgets of academic institutions and small-to-medium-sized biotechnology companies. This financial limitation forces cost-conscious environments to rely on semi-automated or manual workflows, which inherently restricts operational efficiency and throughput capacity. Consequently, the deployment of fully integrated solutions is largely limited to well-funded pharmaceutical organizations, preventing a large segment of potential users from upgrading to advanced automated platforms.
This adoption hurdle is further exacerbated by stagnant funding levels within the public research domain. In 2024, the American Association for the Advancement of Science noted that regular appropriations for the National Institutes of Health were finalized at $47.1 billion, a figure representing stagnant real purchasing power due to inflation. Such budgetary restrictions compel research facilities to delay purchasing capital-intensive equipment. This fiscal conservatism retards the replacement cycle for legacy systems and impedes overall market growth within resource-constrained research sectors.
Market Trends
The incorporation of artificial intelligence into microplate analysis software is transforming data interpretation by automating the quantification of complex phenotypic results. To manage high-content screening datasets, research facilities are utilizing machine learning algorithms, which eliminate manual verification bottlenecks and improve the reproducibility of assay outcomes. This technological shift is supported by the strong uptake of specialized informatics solutions designed to manage data-intensive workflows. In November 2024, during its 'Investor Day', Revvity reported a 12% compound annual growth rate in Annual Recurring Revenue for its SaaS-only Signals software platform, highlighting the growing necessity for intelligent data tools in modern laboratories.
Concurrently, microplate systems are extending their reach into personalized medicine workflows, shifting significantly from upstream research to downstream clinical diagnostics. Clinical labs are utilizing multi-well formats for biomarker validation and large-scale genomic sequencing, which are crucial for stratifying patients based on specific molecular profiles. This expansion into the diagnostic realm generates a stable revenue stream separate from fluctuating R&D budgets, driven by the routine testing requirements of precision healthcare. As reported by Bio-Rad Laboratories in February 2025 within its 'Fourth-Quarter and Full-Year 2024 Financial Results', the Clinical Diagnostics segment achieved full-year net sales of $1.54 billion, a 3.7% rise largely credited to increased consumption of testing products and consumables in clinical settings.
Report Scope
In this report, the Global Microplate Systems Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Microplate Systems Market.
Global Microplate Systems Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: